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which provided an excellent overview of the randomized controlled CORP2 trial, 2 and focused on the role of colchicine in recur rent pericarditis. The authors pointed out that patients with nonidiopathic pericarditis received little benefit from colchicine in the trial. However, we would like to emphasize that the CORP2 trial analysis was not pre specified for these benefits or observations, and the subgroups of patients with non idiopathic pericarditis (such as those with postcardiac injury syndromes, autoimmune disorders, or connective tissue diseases) had too few patients to draw definitive conclu sions.
2 Nevertheless, the CORP2 study 2 showed a >10% reduction in the recurrence of pericarditis in patients treated with col chicine. This reduction is perhaps a sub stantial benefit and might be significant in a largersized prospective study. Until further studies are available to suggest otherwise, the routine use of col chicine in combination with other stand ard therapies for nonidiopathic pericarditis might be a reasonable treatment for these patients. In our own routine practice, we often use a combination therapy of steroids and colchicine for treating patients with autoimmune pericarditis. In our experience, these patients often have better outcomes [3] [4] One aspect of the pericardial disease that remains frustrating, for both clini cians and patients, is multiple recur rences of the disease, which often lead to incessant or refractory pericarditis. In the CORP2 trial, 2 ≥22% of patients experienced recur rent pericarditis despite taking colchicine for 6 months. 2 Although this percent age is approximately half that of patients who were not treated with colchicine, the number is still alarmingly high. A multi drug approach is often used in these patients, which includes the combination of NSAIDs, colchicine, and steroids. 5 Despite this treatment, a large subgroup of patients with recurrent pericarditis might experi ence debilitating repeating symptoms, and improved pharmaceutical alternatives are, therefore, required. Anecdotal reports suggest that interleukin1 inhibitors might be useful in patients with recurrent peri carditis. 5 A small, prospective study in a paedi atric population indicated that anak inra can significantly improve the symptoms of patients with refractory pericarditis. 6 Large, prospective studies are needed to explore the benefit of anakinra and other interleukin inhibitors in adult patients with refractory or recurrent pericarditis. Such future studies will help to f ormulate s tandardized treatment strategies.
